Chemo-immunotherapy before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining chemotherapy with immunotherapy before surgery for esophageal squamous cell carcinoma. It aims to see how these treatments change the tumor environment and may increase the chance of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma.
- Your tumor should be potentially removable with surgery, and you plan to receive standard chemo-immunotherapy before surgery.
- You must be in reasonably good health (ECOG score 0 to 2).
- You must be willing to provide tumor tissue samples before and after treatment.
- You must not have had prior treatment with immune checkpoint inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.